Unraveling the anti-dyslipidemic activity of Pandanus amaryllifollus leaf extract in diabetic rat model: A combined in-vivo and molecular docking approach

The plant Pandanus amaryllifolius Roxb (pandan), has been shown to have antidyslipidemic activity. This study showed the activity of various alkaloids and flavonoids from pandanus leaf that worked as antidyslipidemic. The in-vivo testing was done by taking the blood samples of normal and diabetic male albino rat and assessed the lipid profile. The molecular docking testing was done by the interactions of the alkaloids and flavonoids with the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, Peroxisome Proliferator Activator Receptor (PPAR) alpha and the Niemann Pick C1 Like 1 receptor (NPC1L1) at receptor 1HW9, 6LX4 and 7DFZ respectively. Analyses were carried out by studying the binding affinity of the different alkaloids (pandanamine, pandamarilactonine A and pandamarilactonine B) and flavonoids (catechin, epicatechin, epigallocatechin, kaemferol, myricetin, quercetin) present in pandan leaves. Cholestrol HDL ratio, triglycerides, VLDL decreased and HDL increased. The binding energy of alkaloids pandamarilactonine B at 6LX4 was -9.3 kcal/mol, at 7DFZ were -8.9 and at 1HW9 receptor binding energy of pandamarilactonine A was more negative as compared to standard drug simvastatin showed higher level of interaction between the above mentioned alkaloid, flavonoids and receptors. The studied concluded that pandanus alkaloids and flavonoids have marked good antidyslipidemic activity.